Siemens AG has reported a robust set of financial results for the first quarter of 2026, yet its share price continues to trade significantly below recent highs. This divergence highlights how a major corporate restructuring is currently overshadowing solid fundamental performance in the eyes of investors.
Operational Strength on Display
The industrial conglomerate’s quarterly figures were undeniably positive. Revenue advanced by eight percent to reach €19.1 billion. New orders saw an even stronger increase of ten percent, climbing to €21.4 billion, which pushed the company’s order backlog to a record €120 billion. On a per-share basis, the adjusted profit jumped from €2.22 to €2.80. Given this strong start, management raised its full-year earnings per share (EPS) guidance to a range of €10.70 to €11.10.
Despite these metrics, Siemens stock has failed to gain traction. Currently trading near €218, the shares sit approximately ten percent below their 50-day moving average. They are also down nearly 17 percent from the January peak of €261.55.
The Restructuring Overhang
Market experts point to one dominant factor for this disconnect: Siemens’s planned reduction of its controlling stake in Siemens Healthineers. The company intends to distribute a 30 percent stake in the medical technology unit directly to Siemens shareholders via a spin-off. This move would gradually reduce Siemens’s ownership from about 67 percent to under 20 percent. The strategic goal is to create a more streamlined and focused parent company, centered on its core industrial, digitalization, and AI businesses. Many analysts view this as a potential value-unlocking event for the remaining Siemens core.
Should investors sell immediately? Or is it worth buying Siemens?
However, the lack of concrete details regarding the transaction’s structure and precise timeline is creating uncertainty. The deal remains subject to regulatory approvals and votes at both companies’ annual general meetings. It is this ambiguity, rather than the company’s operational health, that is seen as the primary drag on the share price.
Challenges for the Spinning-Off Unit
Siemens Healthineers faces its own set of hurdles as it moves toward greater independence. By 2028, the company must independently refinance Siemens-guaranteed loans of up to €13.9 billion—a substantial undertaking that requires maintaining a solid investment-grade credit rating. Furthermore, Healthineers anticipates a negative tariff impact of up to €500 million from the U.S. in 2026. Its diagnostics division already contracted by three percent in Q1, partly due to persistent softness in the Chinese market.
Corporate Actions Provide Support
In response to the share price pressure, Siemens is actively executing a share buyback program. The company has already deployed €4.4 billion for repurchases and plans to retire 18 million of its own shares in March. This action will reduce the total number of outstanding shares to approximately 782 million, providing a structural boost to future earnings per share.
Key Dates for Investors
Two upcoming events are critical for the investment narrative. Siemens aims to present detailed plans for the Healthineers spin-off early in the second quarter of 2026, which will serve as a key test for market sentiment. This will be followed by the next quarterly earnings report on May 13. Until the specifics of the corporate transformation are clarified, the restructuring is likely to remain the principal driver of the stock’s direction, regardless of the underlying business performance.
Ad
Siemens Stock: Buy or Sell?! New Siemens Analysis from March 19 delivers the answer:
The latest Siemens figures speak for themselves: Urgent action needed for Siemens investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 19.
Siemens: Buy or sell? Read more here...
